🚀 VC round data is live in beta, check it out!

UCB Valuation Multiples

Discover revenue and EBITDA valuation multiples for UCB and similar public comparables like Merck KGaA, Takeda Pharmaceuticals, Jiangsu Hengrui Pharma, argenx and more.

Start Free TrialSee companies similar to UCB

UCB Overview

About UCB

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).

Founded

1928

HQ

Belgium

Employees

10.1K

Website

ucb.com

Financials (LTM)

Revenue: $9B
EBITDA: $3B

EV

$59B

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

UCB Financials

UCB reported last 12-month revenue of $9B and EBITDA of $3B.

In the same LTM period, UCB generated $7B in gross profit, $3B in EBITDA, and $2B in net income.

Revenue (LTM)

UCB P&L

In the most recent fiscal year, UCB reported revenue of $9B and EBITDA of $3B.

UCB expects next 12-month revenue of XXX and NTM EBITDA of XXX

See UCB forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue$9BXXX$9BXXXXXXXXX
Gross Profit$7BXXX$7BXXXXXXXXX
Gross Margin75%XXX74%XXXXXXXXX
EBITDA$3BXXX$3BXXXXXXXXX
EBITDA Margin34%XXX34%XXXXXXXXX
EBIT Margin25%XXX26%XXXXXXXXX
Net Profit$2BXXX$2BXXXXXXXXX
Net Margin21%XXX20%XXXXXXXXX

Financial data powered by Morningstar, Inc.

UCB Stock Performance

UCB has current market cap of $59B, and enterprise value of $59B.

Market Cap Evolution

UCB's stock price is $310.95.

See UCB trading valuation data
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$59B$59B-0.9%XXXXXXXXX$9.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

UCB Valuation Multiples

UCB trades at 6.3x EV/Revenue multiple, and 18.4x EV/EBITDA.

See valuation multiples for UCB and 15K+ public comps

EV / Revenue (LTM)

UCB Financial Valuation Multiples

As of April 18, 2026, UCB has market cap of $59B and EV of $59B.

Equity research analysts estimate UCB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

UCB has a P/E ratio of 30.6x.

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$59BXXX$59BXXXXXXXXX
EV (current)$59BXXX$59BXXXXXXXXX
EV/Revenue6.3xXXX6.5xXXXXXXXXX
EV/EBITDA18.4xXXX19.0xXXXXXXXXX
EV/EBIT24.7xXXX25.0xXXXXXXXXX
EV/Gross Profit8.4xXXX8.7xXXXXXXXXX
P/E30.6xXXX32.2xXXXXXXXXX
EV/FCF26.3xXXX26.6xXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified UCB Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

UCB Margins & Growth Rates

UCB's revenue in the last 12 month grew by 11%.

UCB's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.4M for the same period.

UCB's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

UCB's rule of X is 59% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for UCB and other 15K+ public comps

UCB Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue Growth11%XXX10%XXXXXXXXX
EBITDA Margin34%XXX34%XXXXXXXXX
EBITDA Growth15%XXX11%XXXXXXXXX
Rule of 40—XXX44%XXXXXXXXX
Bessemer Rule of X—XXX59%XXXXXXXXX
Revenue per Employee—XXX$0.9MXXXXXXXXX
Opex per Employee—XXX$0.4MXXXXXXXXX
S&M Expenses to Revenue32%XXX32%XXXXXXXXX
G&A Expenses to Revenue3%XXX3%XXXXXXXXX
R&D Expenses to Revenue23%XXX24%XXXXXXXXX
Opex to Revenue—XXX48%XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

UCB Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
UCBXXXXXXXXXXXXXXXXXX
Merck KGaAXXXXXXXXXXXXXXXXXX
Takeda PharmaceuticalsXXXXXXXXXXXXXXXXXX
Jiangsu Hengrui PharmaXXXXXXXXXXXXXXXXXX
argenxXXXXXXXXXXXXXXXXXX
ZoetisXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

UCB M&A Activity

UCB acquired XXX companies to date.

Last acquisition by UCB was on XXXXXXXX, XXXXX. UCB acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by UCB

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

UCB Investment Activity

UCB invested in XXX companies to date.

UCB made its latest investment on XXXXXXXX, XXXXX. UCB invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by UCB

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About UCB

When was UCB founded?UCB was founded in 1928.
Where is UCB headquartered?UCB is headquartered in Belgium.
How many employees does UCB have?As of today, UCB has over 10K employees.
Who is the CEO of UCB?UCB's CEO is Jean-Christophe Tellier.
Is UCB publicly listed?Yes, UCB is a public company listed on Euronext Brussels.
What is the stock symbol of UCB?UCB trades under UCB ticker.
When did UCB go public?UCB went public in 1988.
Who are competitors of UCB?UCB main competitors are Merck KGaA, Takeda Pharmaceuticals, Jiangsu Hengrui Pharma, argenx.
What is the current market cap of UCB?UCB's current market cap is $59B.
What is the current revenue of UCB?UCB's last 12 months revenue is $9B.
What is the current revenue growth of UCB?UCB revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of UCB?Current revenue multiple of UCB is 6.3x.
Is UCB profitable?Yes, UCB is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of UCB?UCB's last 12 months EBITDA is $3B.
What is UCB's EBITDA margin?UCB's last 12 months EBITDA margin is 34%.
What is the current EV/EBITDA multiple of UCB?Current EBITDA multiple of UCB is 18.4x.
What is the current FCF of UCB?UCB's last 12 months FCF is $2B.
What is UCB's FCF margin?UCB's last 12 months FCF margin is 24%.
What is the current EV/FCF multiple of UCB?Current FCF multiple of UCB is 26.3x.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial